To reinforce this hypothesis are results of our subgroup analysis conducted in HR+ BC patients, which revealed a significant advantage, in terms of both PFS and OS, with CV over C specifically in ER+ PgR+, but not in ER+ PgR- patients (Figure S2). The gene discussed is ESR1; the disease is breast cancer.